of innovative cancer drugs since the implementation of this reimbursement price cap. Abstract: Methods:Methods: This …'Hospitalisation) and included 487 hospitals, which were public and non-profit private. The analysis was conducted on the cancer drugs of …

The objective of this paper is to examine how well the QALY captures the health gains generated by cancer treatments … insensitive to changes in health status of cancer patients. Second, the time trade-off, NICE's preferred technique for estimating … individuals typically display a misunderstanding of what it is really like for patients to live with cancer. Because of the way in …

) programme to assess several drugs for cancer. Typically, the evidence submitted by the manufacturer comes from one short …

of cancer protocols or from primary data collection. The resources were costed from a healthcare system perspective using … cancers: locally advanced and metastatic non-small-cell lung cancer, adjuvant colorectal cancer and adjuvant breast cancer …. Abstract: Results:Results: For the three cancer types examined, the cost of completed administration ranged from 1274 …

Globally, there are approximately 7.4 million cancer deaths annually, approximately 13% of deaths from all causes …. Cancer is a disease of older people and, as the population ages over the next 10-20 years, we can expect an increase in the … cancer incidence. Encouragingly, cancer mortality has stabilized in many countries. Part of this success may be attributed to …

Therapy for long term anticoagulation in cancer patients with venous thromboembolism]), which evaluated secondary prophylaxis … of venous thromboembolism (VTE) in cancer patients, dalteparin reduced the relative risk of recurrent VTEs by 52 … cancer. …

Cancer is one of the most frequent disease-specific applications of the EQ-5D. The objective of this review was to … summarise evidence to support the validity and reliability of the EQ-5D in cancer, and to provide a catalogue of utility scores … based on the use of the EQ-5D in clinical trials and in studies of patients with cancer. A structured literature search was …

with advanced breast or prostate cancer, zoledronic acid 4 mg every 3-4 weeks for up to 15 months significantly reduced the … breast cancer or multiple myeloma, the incidence of SREs was similar in patients treated with zoledronic acid 4 mg or … pamidronic acid 90 mg every 3-4 weeks for up to 25 months but, in breast cancer patients, zoledronic acid reduced the risk of …

Anaemia develops in most patients undergoing cancer therapy and invariably induces fatigue, which is a major … cancer patients. The number of patients needed to be treated with epoetins to avoid the transfusion of one unit of blood … 1 blood unit. Despite this, epoetins have been widely adopted by industrialised countries, where cancer patients are …

treatment of anaemia. Their successful use in the treatment of anaemia associated with renal disease, cancer and other diseases … resources. Much of the recent literature on ESAs in the treatment of anaemia associated with chronic kidney disease and cancer …